Method Of Mobilizing Pluripotent Hematopoietic Stem Cells And Accelerating Leukocyte Reconstitution With IL-7
Description of Invention:
This invention provides a method of increasing the number of hematopoietic stem cells in a subject by administering interleukin-7. Hematopoietic stem cells are distinguishable from hematopoietic progenitor cells in that the stems cells are pluripotent and not yet committed to myeloid or lymphoid lineages. After treatment, a population of leukocytes enriched for hematopoietic stem cells may be transferred into a recipient in order to enhance the repopulation of the recipient's hematopoietic and immune cells. This method provides for improved leukocyte engraftment of bone marrow transplants in a recipient following transplantation or irradiation.
Potential Area of Application:
bone marrow transplants
peripheral blood transfusions
treating immunodeficiency
Main Advantage of Invention:
improved engraftment of transplants
minimized toxicity from chemotherapy and/or radiation
increased efficiency of stem cell procurement
Stage of Development:
demonstration that rhiIL-7 administration to mice affects mobilization of leukocyte stems cells and precursors
no observable toxic effect of long-term ( 6 weeks) rhIL-7 treatment
Patent Status:
DHHS Reference No. E-139-1994/0 --
U.S. Patent 5,637,323 issued 10 Jun 1997
No foreign rights
Relevant Publication:
KL Komschlies, KJ Grzegorzewski, RH Wiltrout. Diverse immunological and hematological effects of interleukin 7: implications for clinical application. J Leukoc Biol. 1995 Dec;58(6):623-633. [PubMed abs]
OC Boerman, TA Gregorio, KJ Grzegorzewski, CR Faltynek, JJ Kenny, RH Wiltrout, KL Komschlies. Recombinant human IL-7 administration in mice affects colony-forming units-spleen and lymphoid precursor cell localization and accelerates engraftment of bone marrow transplants. J Leukoc Biol. 1995 Aug;58(2):151-158 [PubMed abs]
KJ Grzegorzewski, KL Komschlies, SEW Jacobsen, FW Ruscetti, JR Keller, RH Wiltrout. Mobilization of long-term reconstituting hematopoietic stem cells in mice by recombinant human interleukin-7. J Exp Med. 1995 Jan 1;181(1):369-374 [PubMed abs]
Licensing Status: Available for exclusive or non-exclusive licensing
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics Internal Medicine-Therapeutics
For Additional Information Please Contact: Surekha Vathyam Ph.D.
Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4076
Email: vathyams@mail.nih.gov
Fax: 301/402-0220
